Ace Therapeutics offers comprehensive services in studies targeting the programmed cell death (PCD) process for the development of nonalcoholic fatty liver disease (NAFLD) therapies. With years of experience and multiple validations, we have established comprehensive services for the development of NAFLD therapies targeting PCD to facilitate the smooth conduct of your studies.
PCD, especially in hepatocytes, plays a key role in the pathology of NAFLD. PCD has multiple forms including apoptosis, necroptosis, autophagy, pyroptosis, and ferroptosis. By acting on the interactions between different PCDs and their associated targets, more effective therapeutic approaches can be developed and even personalized treatments can be achieved.
What Can We Do?
Development Services for MAFLA Therapies Targeting PCD
Ace Therapeutics has extensive experience in targeted drug development. We have advanced technology platforms and a scientific knowledge system to support us in providing the most appropriate assistance on your research path.
- Targeting PCD-Related Targets
Different forms of PCD often involve specific targets. It is an effective way to target these specific targets to regulate the pathological process of NAFLD. Based on our decades of research experience, we provide comprehensive drug development services targeting PCD-related targets. We have established gene microarray and protein microarray approaches for PCD to comprehensively screen for PCD-specific targets.
- Targeting PCD Interactions
Different forms of PCD have complex interactions to influence the pathological process of the disease. Therefore, it is a viable strategy to develop therapies for NAFLD targeting PCD interactions. We will explore the interactions between different forms of PCD through different biotechnologies such as protein interactions to discover potential therapeutic targets. To some extent, the success rate of NAFLD can be increased by developing drugs that act on multiple PCDS and multiple pathways. Targeting PCD interactions
Drug Screening Platforms
- High Throughput Screening Platform
- High Content Imaging Platform
- Target-Based Drug Screening Platform
- Fragment-Based Drug Screening Platform
Preclinical Pharmacology Services
Ace Therapeutics provides NAFLD-related cellular and animal models for pharmacological proof-of-principle studies of candidate NAFLD therapies to fully evaluate their efficacy and explore their pharmacological mechanisms of action. Our scientists have extensive research experience in animal models, detection, and endpoint of NAFLD. In addition, to meet the specific needs of your experiment, we can design and customize new experimental models for you.
- We offer different in vitro and in vivo NAFLD models to suit different research needs.
- We offer a wide range of assays for characteristic biomarkers of PCD processes, such as cystathione or cytokeratin-18 (CK-18) fragments cleaved by cystathione 3, RIPK3, RIPK1, MLKL, and characteristic pathological processes, such as mitochondrial stress, endoplasmic reticulum stress, and lipid metabolism.
Ace Therapeutics provides high-quality and efficient services to develop NAFLD therapies for PCD. We have a team of experienced scientists, researchers, and technical staff to provide fast turnaround and high-quality services for the development of liver disease therapies for our clients worldwide. If you would like to learn more about our services, please feel free to contact us.
Reference
- Zhao, J., et al., Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (mafld): A promising new therapy. Cell Mol Biol Lett, 2021. 26(1): p. 17.
Our products and services are for research use only and can not be used for diagnostic or other purposes.
